SAN Sanofi

Sanofi: Information concerning the total number of voting rights and shares - September 2022

Sanofi: Information concerning the total number of voting rights and shares - September 2022

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)

Sanofi

a French société anonyme with a registered share capital of 2,534,952,234 €

Registered office : 54, rue La Boétie - 75008 Paris - France

Registered at the Paris Commercial and Companies Registry under number 395 030 844

Date 



Total number of

issued shares



 		Number of real

voting rights

(excluding treasury shares)		Theoretical number of

voting rights

(including treasury shares)*
September 30, 20221,267,479,7661,411,899,2281,425,326,874

* Pursuant to article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.

This information is also available on the internet website of sanofi under « Regulated Information in France »:

Investor Relations Department

e-mail:



 



 

Attachment



EN
13/10/2022

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s high-dose influenza vaccine demonstrates super...

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p

1h 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi dé...

Communiqué de presse : Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Le vaccin antigrippal à haute dose de Sanofi démontre une protection supérieure contre les hospitalisations chez les séniors par rapport aux vaccins à dose standard Par rapport aux vaccins antigrippaux à dose standard, Efluelda/Fluzone High-Dose a démontré sa capacité à réduire de 31,9 % supplémentaires (IC à 95 % : 19,7 à 42,2 ; p

1h 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHM...

Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant improvements in bleeding, quality of life measures, and other ITP symptoms   If approved, Wayrilz will be the first BTK inhibitor for ITP in the EU, targeting the root cause of the disease through multi-immune modulation Paris, October 17, 2025. The European Medicines Agency’s Committee ...

October 17, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour ê...

Communiqué de presse : Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire Wayrilz de Sanofi recommandé par le CHMP pour être approuvé par l’UE dans le cadre du traitement de la thrombocytopénie immunitaire Recommandation fondée sur l’étude de phase 3 LUNA 3 démontrant une réponse plaquettaire rapide et durable, ainsi que des améliorations significatives en termes de saignements, de qualité de vie et d’autres symptômes de la TPI. S’il est approuvé, Wayrilz sera le premier inhibiteur de la BTK pour la TPI dans l...

October 17, 2025 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi provides update on regulatory review in the EU f...

Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion on the marketing authorisation application for Rezurock (belumosudil) for the third-line treatment of adults and pediatric patients with chronic graft-versus-host disease (cGVHD). Sanofi will seek a re-examination of the CHMP op...

October 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch